Cannabis legislation is threatening to reduce pharmaceutical stock value by billions of dollars as more people are predicted to opt for weed over opioids.
Medical cannabis remains difficult to attain in healthcare under the British government, but it holds great promise for both NHS patients and the economy.
Optimising a drug’s ability to reach diseased body parts in adequate levels while avoiding healthy body parts – its tissue exposure and selectivity – is critical to therapeutic optimisation.
Nick Morland, Tenacious Labs CEO, All-Party Parliamentary Group for CBD Products Secretariat, Jersey Cannabis Services Advisory Board Chair, writes about the UK Cannabis Industry – could this be the next Scottish Whisky?
One million homes will be given cannabis plants across Thailand, to mark the legalisation and attract foreign tourists – to be used for ‘medicinal purposes’ only.
